

ACT-Accelerator & COVAX


MS COVID-19 Briefing

11 MARCH 2021

ACT now, ACT together to accelerate the end of the COVID-19 crisis

Updates

1. Release of ACT-Accelerator Strategy & Budget for 2021
2. Major upcoming events
 - Facilitation Council pre-briefing (19 March)
 - 5th Facilitation Council Meeting (23 March)
3. COVAX roll-out & risks




The ACT-Accelerator is evolving in a rapidly changing world....


...the new strategy for 2021 reflects these changes

Major aspects of the new ACT-A plan for 2021....


Sharper Strategic & Pillar priorities



Sequencing of priority activities in 2021




Updated needs & financing gap




Pillar achievements 2020

	R&D and product assessment	Market shaping & manufacturing	Procurement	Demand generation & in-country delivery
Vaccines	Established portfolio of 11 vaccine candidates across 4 technology platforms	Established the identification & supply and no-fault compensation programme for AMC countries	Established the COVAX facility for procurement and equitable distribution of vaccines to 200 countries → 2.5 bn doses secured through 8 deals 237 million doses allocated to facility participants (Pfizer, AZ, J&J, etc.) of which 194 million doses for AMC countries for February to May	Supported the development of at least 102 National Development and Vaccination Plans Delivery of first COVAX doses to AMC countries within 12 weeks after first country started vaccinating, with a total of 101 doses delivered to 8 countries as of March 3
Diagnostics	Expedited development and regulatory approval of quality tests, supporting product selection (Ag-RTL) received WHO EUL	Facilitated the introduction of Ag-RTL, reducing the cost of the test for LMICs to US\$ 2.50 in 2021 and further to US\$ 2.50 in 2021	Procured 650 million molecular and Ag-RTLs for LMICs	Supported 70+ countries in expanding laboratory infrastructure and ramping up testing Developed policy and implementation guidance, testing tools and technical assistance
Therapeutics	Tracked 300 actionable trials across products (mAb, novel antivirals and repurposed therapeutics) Supported 2 large randomized controlled platform trials and identification of the first life-saving therapy (dexamethasone) and provided global guidance on its use	Identified US\$ 500m immediate funding needs for medical oxygen in up to 20 LMICs	Facilitated and supported the use of dexamethasone, securing 2.8 million treatment courses	Formed COVID-19 Oxygen Emergency Taskforce to assess and address COVID-19 surges in oxygen demand and cut preventable deaths
Health Systems Connector		Procured PPE for a total value of US\$ XXX million	Mapped system requirements for the introduction of new COVID-19 tools in 4 out of 7 world regions Conducted national public surveys in 19 countries to assess bottlenecks Established common knowledge sharing platform Developed global guidelines and training across multiple critical health system areas	

Complementary financing



Financing framework & accountabilities



WHO SPRP, CEPI Investment Case and other ACT-A agency plans fully aligned

In 2021 ACT-A has 4 strategic priorities, driving for equity, while continuously improving these tools



1

Rapidly scale-up
delivery of >2 B
vaccine doses



2

Bolster R&D, eval & reg
paths to **address variants**
& **optimize products**



3

Stimulate rapid **uptake**
of tests, therapeutics
& **PPE**



4

Ensure **robust supply**
pipeline of essential
tests, treatment & PPE

Pillar-specific priorities & deliverables underpin the **4 cross-cutting, strategic priorities**

Pillar-specific priorities for 2021



Vaccines

1. deliver >2 B doses thru COVAX Facility in 2021, with >1.3 B in AMC countries, to cover initial high-risk target groups:
2. **Support country ambitions to end pandemic (eg expand coverage & capacity, starting with >500 m add'l doses in '21)**
3. Ensure equitable access & fair allocation of vaccines
4. Accelerate & expand R&D for programmatically-optimized vaccines that also address risks due to variants



Diagnostics

1. **Ensure equitable access to new and existing tests, incl. distribution of at least 900 million molecular and Ag-RDTs**
2. Stimulate rapid and effective uptake of appropriate and quality-assured diagnostics in countries
3. Drive development and at-scale availability of affordable, transformative, digitally- integrated tests.



Therapeutics

1. **Ensure uptake of existing products, incl. oxygen and corticosteroids for up to 12 m severe & critical patients**
2. Introduce new therapies for 100 m treatment courses across all use cases, subject to evidence and availability
3. Accelerate & intensify research to expand the clinical pipeline, broadening the portfolio of effective tools, incl. combinations of therapeutics



Health Systems Connector



1. **Fully integrate the work and products of the Pillars with a strengthened, ongoing COVID-19 response**
2. Rapidly address country health systems bottlenecks to ensure readiness, rapid scale up & delivery of tools
3. Accelerate PPE availability & use as a crucial tool to protect health workers and ensure resilience health system
4. **Manage linkages with complementary activities in essential health services & HSS**

Recognizing ACT-A's generous contributors & updating the gap

A broad coalition of public (87%), private (6%) & multilateral donors (7%)

ACT-A contributors¹ as of 11 March 2021

ACT-A US\$22.1 B financing gap for 2021



Note: all financial commitments can be accessed at <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>.

1. US\$ 11 billion include \$470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs

2. Contributions <US\$ 12m, and including \$470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs

Major Upcoming ACT-A Events

5th ACT-A Facilitation Council

23 March 2021, 12:30-15:00hr CET (Geneva time)

AGENDA FOCUS:

1. **Achieving our ACT-A diagnostics & therapeutics goals for 2021: what's holding us back?**

Facilitated panel discussion with Council Members

2. **Where do we have to focus to rapidly scale up vaccine supply to COVAX?**

Interactive panel with CEPI, WHO, Countries, CSOs & Council

Proceeding will be livestreamed for all Member States on the [ACT Accelerator site](#)

5th ACT-A Facilitation Council – preparations

Technical Pre-briefing:

- Date: Friday, 19 March, 12:30-14:00 hr CET (Geneva time)
- Focus: **COVID-19 Diagnostics & Therapeutics** - state of play & next steps
- Invitees: Council Members & WHO Member States (Permanent Missions)
- Format: overview presentations and Q&A

Member State delegations can register [HERE](#)

COVAX Rollout, Risks & Scale-up

1st wave of COVAX deliveries kicked off 24 February

24 February

The first batch of COVAX doses has arrived in Ghana (600,000 doses)



26 February

South Korea receives 117,000 COVAX doses




2 March

3.94 million doses of COVAX vaccines arrive in Nigeria



26 February

504,000 doses have landed in Côte d'Ivoire



1 March

Côte d'Ivoire and Ghana start their first COVID-19 COVAX vaccinations



...

30 m COVAX doses delivered to 36 countries in just 2 weeks

2 March

First COVAX doses also arrived in Angola, Cambodia, DRC and Gambia



4 March

Philippines receives first doses from Astrazeneca



3 March


First COVAX doses arrived in Rwanda, Kenya and Sudan



- More shipments in coming days & weeks
- Planned shipments for next 7 days available on [UNICEF Vaccine market dashboard](#) (see “Delivery” tab)


COVID-19 Vaccine Rollout: current status

NEW: WHO COVID-19 dashboard now includes vaccination




COVAX rollout to date: 30 m doses delivered to 36 countries

Number of COVAX deliveries, by date, as of 11 March 2021



Cumulative doses delivered, by supplier, as of 11 March 2021¹




¹ an additional 10m doses supplied to India through COVAX

NEW: Public COVAX roll-out dashboard resources

1. UNICEF for POs and planned shipments

<https://www.unicef.org/supply/covid-19-vaccine-market-dashboard>



2. Gavi for deliveries

<https://www.gavi.org/live/covax-vaccine-roll-out>



Scaling & Sustaining the COVAX Rollout – key risks at 10 March

1. Manufacturer level:

Serum Institute of India (suppliers to 60 COVAX countries) – **sustaining volumes**

AstraZeneca/SK Bio (supplier to 85 COVAX countries) - **packaging & shipping capacity**

Pfizer (supplier to an initial 18 COVAX countries) - I&L & shipping capacity

2. Country level:

13 of the COVAX participants that have not yet started vaccination, still lack key pre-requisites (e.g. I&L, regulatory authorization, financing)

The biggest risk to COVAX rollout to LMIC/LICs is the increasing competition & demand on key COVAX suppliers (i.e. SII, AZ)